ArticleEuropean journal of heart failure2025

Targeting dipeptidyl peptidase 3 (DPP3) in extreme-critically ill patients with refractory shock: First-in-human report on the safety and efficacy of an anti-DPP3 antibody.

Dominik Jarczak et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.